Markets enter a holiday-shortened week with the Martin Luther King, Jr. Day closure Monday, followed by a convergence of events including President Trump's inauguration speech Wednesday at 8:30am
These two income stocks can weather every cycle.
TECVAYLI ® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI ® ...
New CAPLYTA ® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented
Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months
Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.
Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates Agreement provides Johnson & Johnson pharmaceutical products...
- Number of Lawsuits Increases Fivefold to Over 2,100 Since May - FDA Approves Brain Tumour Warning Global pharmaceutical company...
Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.